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A kit-based aluminium-[18F]fluoride approach to radiolabelled 
microbubbles 
Jin Hui Teh,a,b Marta Braga,b Louis Allott,b,c Chris Barnes,b Javier Hernández-Gil,a,b Meng-Xing 
Tang,d Eric O. Aboagye,*b Nicholas J. Long*a 
The production of 18F-labelled microbubbles (MBs) via the 
aluminium-[18F]fluoride ([18F]AlF) radiolabelling method and facile 
inverse-electron-demand Diels-Alder (IEDDA) ‘click’ chemistry is 
reported. An [18F]AlF-NODA-labelled tetrazine was synthesised in 
excellent radiochemical yield (>95% RCY) and efficiently conjugated 
to a trans-cyclooctene (TCO) functionalised phospholipid (40-50% 
RCY), which was incorporated into MBs (40-50% RCY). To 
demonstrate the potential of producing 18F-labelled MBs for clinical 
studies, we also describe a kit-based approach which is amenable 
for use in a hospital radiopharmacy setting. 
Microbubbles (MBs) are widely used to enhance ultrasound 
(US) contrast in echocardiography, characterise lesions, and 
evaluate perfusion.1  These ultrasound contrast agents consist 
of a gas core encapsulated by a stabilising shell, usually made 
up of phospholipids, proteins, or polymers. With a size of 1-5 
µm, MBs are restricted to the vasculature, but recent 
developments in targeting ligands have enabled these contrast 
agents to image diseases at a molecular level.2 In this regard, 
the conjugation of a targeting ligand to the microbubble shell 
enables active targeting of angiogenesis,3,4 inflammation,5 
thrombosis,6 and tumours.7,8 A phospholipid-based 
formulation, BR55, has also shown promising results recently 
for detecting various cancer types during humans trials.9,10 
 Despite these advances, clinical translation of these 
targeted microbubbles remains challenging, partly due to the 
localised nature of ultrasound imaging.11 This makes it difficult 
to monitor the biodistribution and pharmacokinetics of new 
microbubble formulations.  
 To overcome this, several groups have developed dual 
modal positron emission tomography/ultrasound (PET/US) MB 
formulations to allow the assessment of microbubble 
biodistribution, making use of the high sensitivity and 
penetration depth of PET.12–14 However, two of these 
formulations use streptavidin-biotin interactions for the 
incorporation of the fluorine-18 (18F) isotope, making them 
unsuitable for human use due to their immunogenicity.13,14 
Promisingly, Ferrara et al. radiolabelled a lipid molecule by 18F-
nucleophilic substitution, thus eliminating the need for 
streptavidin-biotin interactions.12 However, the radiolabelled 
lipid was purified in hexane and evaporated in a nitrogen 
stream; this is a challenging procedure to implement for the 
production of clinical-grade radiopharmaceuticals, and the 
toxicity of the solvent requires rigorous quality control 
validation to ensure its absence from radiopharmaceutical 
formulation. Expertise in organic 18F-fluorination chemistry and 
specialist production facilities are also required to produce 
these MBs, presenting a potential obstacle to their clinical and 
routine use.15 
 To ameliorate these concerns, our group recently reported 
a convenient radiometal chelation approach, in combination 
with inverse electron demand Diels Alder (IEDDA) chemistry, to 
radiolabel MBs using gallium-68 (68Ga, t1/2 = 68 min, Eβ+, max = 1.9 
MeV).16 Although the microbubbles can be produced within 50 
minutes from 68Ge/68Ga generator elution, the relatively short 
half-life of 68Ga, and somewhat onerous manual radiosynthesis 
process, reduce opportunities for further functionalisation (i.e. 
with targeting moieties). Furthermore, the limited production 
capacity of 68Ge/68Ga-generator reduces the number of patient 
doses from one elution of the generator, resulting in lower 
patient throughput.17 
 To overcome these challenges, and to improve the 
accessibility of 18F-labelled MBs over previous studies, we 
designed a convenient and facile 18F-microbubble labelling 
method using aluminium-[18F]fluoride ([18F]AlF) radiochemistry. 
The [18F]AlF method reported by McBride et al. combines the 
favourable decay characteristics of 18F (t1/2 = 110 min, Eβ+, max = 
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0.64 MeV), with the convenience of metal-based 
radiolabelling.17–23  
 In brief, the aluminium-[18F]fluoride ([18F]AlF) method was 
used to radiolabel a tetrazine-containing prosthetic group (PG) 
and subsequently conjugated to trans-cyclooctene (TCO) 
functionalised lipids via the rapid IEDDA reaction (Figure 1). 
 A lipid-based microbubble formulation was chosen due to 
its versatility and widespread application.16,24 Dipalmitoyl 
phosphatidylcholine (DPPC) and dipalmitoyl phosphate (DPPA), 
which are biocompatible surfactants used in drug delivery 
vehicles,25 form the bulk of the stabilising microbubble shell; 
whereas DSPE-PEG2000-NH2 stabilises microbubbles from 
coalescence, increases circulation time, and acts as a handle for 
ligand conjugation.26 Using a formulation of 75:10:10:5 mol% 
DPPC:DPPA:DSPE-PEG200-TCO:DSPE-PEG2000-NH2, microbubbles 
were produced with precise concentration and size profiles 
(Figure 2). This was in agreement with our previous 
formulation,16 as confirmed by optical microscopy and zeta 
potential measurements. With the TCO functionality 
successfully incorporated into the microbubbles, this 
formulation was carried forward for 18F-labelling.  
 A tetrazine-functionalised 1,4,7-triazacyclononane-1,4-
diacetate (NODA) chelator was synthesised by amide coupling 
tetrazine (1) and NODA-methylphenyl acetic acid (2) to produce 
(3) (Scheme 1). The NODA macrocycle was selected for this 
study because pentadentate chelators radiolabel more 
efficiently in higher radiochemical yield (RCY) than hexadentate 
chelators, where the free carboxylate arm competes with 18F- 
for the final Al coordination site.19,27  
 Upon deprotection of (3) to reveal the carboxylate arms, 
NODA-tetrazine (4) was radiolabelled with [18F]AlF in  >95% RCY 
and >95% radiochemical purity (RCP) after optimisation (Tables 
S1-3). The product identity and reaction efficiency were 
determined by radio-HPLC and radio-TLC (Fig. S3). [18F]AlF-Tz 
was purified by using a solid phase extraction (SPE) cartridge 
(Oasis Prime HLB), and used in subsequent IEDDA reactions with 
DSPE-PEG200-TCO. In total, [18F]AlF-Tz was synthesised and 
purified in under 30 mins.  
 Decomposition of [18F]AlF-Tz occurred in EtOH at rate of 3-
5% per hour (Table S5). Although this phenomena was observed 
in similar [18F]AlF-tetrazine molecules, presumably due to 
decomposition of the tetrazine moiety, the effect on the 
tetrazine-TCO conjugation is minimal if the reaction is carried 
out promptly after isolation of the [18F]AlF-tetrazine.28,29  
 Following successful isolation of [18F]AlF-Tz, the efficiency of 
the tetrazine-TCO conjugation reaction was examined. A 
purified fraction of [18F]AlF-Tz in EtOH was conjugated to an 
equimolar quantity of DSPE-PEG200-TCO, resulting in 40-50% 
conversion after heating at 60 oC for 20 min (non-isolated 
product, determined by radio-HPLC, Figure 3). The appearance 
of a new peak with longer retention time (Rt = 7:35 min:sec) 
than the precursor (Rt = 1:29) corresponds to the formation of 
the [18F]AlF-lipid, which was also confirmed by radio-TLC (Fig. 
S4). 
 Direct labelling of phospholipids by [18F]AlF was not 
investigated due to lipid hydrolysis under the acidic conditions 
necessary for [18F]AlF radiolabelling (pH 4 - 5),30 and the 
irreversible retention of these lipid compounds on a range of 
cartridges.16  
 
Figure 2: Left: Optical microscopy image of microbubbles; Right: Size 
distribution of microbubbles. 
Scheme 1: Synthesis of [18F]AlF-Tz. Reaction conditions: a) HBTU, 
Et3N, DMF, 40 oC, 24 h; b) TFA, CH2Cl2, r.t., 24 h; c) AlCl3, [18F]F-, 0.5 
M sodium acetate:MeCN 2:3 v:v, pH 4.2, 100 oC, 20 min.
Figure 1: Schematic representation of 18F-labelling of microbubbles developed in this study, where radiolabelling is achieved by reaction of a 
TCO-containing lipid (DSPE-PEG200-TCO) and a tetrazine-functionalised 18F prosthetic group. Step A: 18F-labelling of chelator (>95% RCY, RCP); 
Step B: IEDDA reaction of 18F-labelled chelator and TCO-lipid (40-50% RCY); Step C: Formation of [18F]AlF-microbubbles (40-50% RCY).
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 Next, the [18F]AlF-lipid was incorporated into MBs together 
with DPPC, DPPA and DSPE-PEG2000-NH2. Unreacted [18F]AlF-Tz 
and remaining free lipids were removed by a centrifugal 
purification methodology.16 Once centrifuged, microbubbles 
were collected as a concentrated layer of foam at the top of the 
vial, and unincorporated components remained in the 
infranatant. This generated [18F]AlF-MBs (48 ± 12 MBq) in good 
RCY (31 ± 5 % decay corrected to start of synthesis), and 
concentrations of (4.32 ± 0.90)·108 microbubbles/mL, within in 
60-70 mins. Incorporation of the [18F]AlF-lipid into microbubble 
shells was confirmed by radio-HPLC-analysis of the centrifuge 
washing infranatant, which show a decreased percentage of the 
[18F]AlF-lipid compared to the [18F]AlF-Tz (Fig. S5), inferring the 
incorporation of [18F]AlF-lipid into the MBs.  
 Successful 18F-labelling of MBs was also confirmed during 
the centrifugal purification process, by comparing the activity of 
the infranatant from successive centrifugal washes to that of 
the remaining microbubble foam layer (Figure 4). Following the 
third wash, almost all remaining activity (>95%) resulted from 
the microbubbles. To prove that the radioactivity of the [18F]AlF-
MBs was specific to [18F]AlF-lipid and not [18F]AlF-Tz, the 
microbubbles were dissolved in methanol and analysed by 
radio-HPLC. The resulting chromatogram showed only [18F]AlF-
lipid, with no [18F]AlF-Tz detected (Fig. S6). 
 To minimise unnecessary exposure to radioactivity when 
synthesising [18F]AlF-Tz, the radiosynthesis was automated 
using the GE FASTLabTM platform. An automated sequence was 
developed and [18F]AlF-Tz was produced from larger starting 
activities of [18F]fluoride (1067 ± 58 MBq) in 60-66% RCY within 
45-50 mins (details in SI). This was consistent with a reported 
automated synthesis of a similar [18F]AlF-tetrazine conjugate.29 
 Automation enabled the production of [18F]AlF-MBs in 
higher activities of 136 ± 6 MBq. The results of the [18F]AlF-MBs 














Manual 227 ± 25 48 ± 12 31 ± 5 60-70  
Automated 1067 ± 58 136 ± 6 22 ± 1 85-90  
Kit-based 65 ± 5 13 ± 2 30 ± 2 50-60 
Table 1: Comparison of 18F-labelled microbubble production using 
the manual, automated, and kit-based approaches. Reactions were 
performed in triplicate (n=3), values presented as mean ± SD. 
 To support the potential clinical translation of this method, 
we developed a kit-based approach to producing the [18F]AlF-
MBs. It was reasoned that a kit-based TCO-microbubble 
formulation could potentially be 18F-labelled in one pot (Figure 
5), owing to the fast reaction kinetics of the tetrazine-TCO 
IEDDA reaction.31 This would facilitate the development of new 
phospholipid-based MB formulations, including targeted MBs, 
since the TCO-functionalised lipid and biomolecule-lipid 
conjugate could be lyophilised with the other lipid components 
in the same vial prior to activation to form microbubbles, similar 
to existing commercial microbubble formulations.  
 To investigate this, DSPE-PEG200-TCO was mixed and 
lyophilised in the same vial containing the rest of the lipids. 
Following resuspension of the lipids in a mixture of propylene 
glycol:glycerol:PBS (15:5:80), [18F]AlF-Tz in ca. 80 µL of EtOH was 
added. The vial was then sealed and purged with 
perfluorobutane, and agitated to form microbubbles by 
mechanical shaking for 1 min. To ensure sufficient time for the 
tetrazine-TCO ligation, the microbubble suspension was left to 
stand for a further 5 mins before centrifugal purification.  
 The resulting microbubble suspension showed a 40-50% 
incorporation of radioactivity, consistent with the [18F]AlF-Tz 
TCO reaction yield. Analysis of the microbubble infranatant 
following centrifugal purification gave an identical profile to 
previous described experiments (Figure 4), highlighting the 
feasibility of a kit-based TCO-lipid formulation for 18F 
radiolabelling of microbubbles. 
 To further facilitate the kit-based labelling procedure, such 
that the purification of [18F]AlF-Tz could be eliminated, the 
reaction co-solvent for 18F-labelling of the chelator was changed 
from MeCN to EtOH, a more good manufacturing process (GMP) 
Figure 3: Radio-HPLC chromatogram showing the formation of 
[18F]AlF-lipid (tR = 7:25 mm:ss) from [18F]AlF-Tz (tR = 1:29 mm:ss) via 















Figure 4: Comparison of activities of microbubble foam against 
infranatant after successive centrifuge washes. Reactions were 
performed in triplicate (n=3), values presented as mean ± SD.
    
    
    
    
    
   
   
    
    
    
    
    
    
    
    
    
     


















           
           
           
Figure 5: Development of a kit-based approach for 18F-labelling of 
microbubbles.
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compatible solvent (Figure 1, step A). Interestingly, EtOH as the 
co-solvent resulted in a lower reaction yield (80%), compared to 
MeCN, which exhibited full (>95%) incorporation of [18F]AlF 
after 20 min. Nonetheless, extending the reaction time to 30 
mins resulted in >95% [18F]AlF chelation, thereby eliminating 
the need for a cartridge-based purification prior to incubation 
with the microbubbles. Using this kit-based approach, [18F]AlF-
MBs could be produced in 30 ± 2% RCY, consistent to that of the 
previous methods, albeit with a lower activity of 13 ± 2 MBq. 
The decreased activity of the microbubbles is sufficient for 
multi-animal in vivo biodistribution studies, with currently 
reported studies requiring only 0.37-7.4 MBq for each 
injection.12–14,16 Since (1-5)·107 MBs are required per injection 
for pre-clinical US imaging, and this work generates 
microbubbles with activities of 0.3-3.2 MBq/107 microbubbles, 
the requirements for both PET and US imaging are met, 
enabling the [18F]AlF-MBs to be used for both modalities in the 
same study.  
 In conclusion, we present the first method to generate 
[18F]AlF-labelled microbubbles. This approach offers a 
convenient method to generate radiolabelled microbubbles 
with higher activities, and hence larger dose, compared to 
previous attempts with 68Ga and 18F. The facile [18F]AlF-labelling 
procedures and efficient tetrazine-TCO IEDDA ‘click’ reaction 
also enable reliable and reproducible generation of the [18F]AlF-
MBs. Using this robust method, we designed and developed the 
first kit-based approach for producing radiolabelled 
microbubbles with clinical translation in mind. With the 
continued development of new microbubble formulations 
bearing targeting vectors for molecular ultrasound imaging, this 
kit-based approach would enable easy customisation of new 
phospholipid-based formulations for early in vivo evaluation of 
their pharmacokinetics and biodistribution.  
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